CDR-101

N/A

Report date: 2026/03/19 16:59:53

Base Information

Drug NameCDR-101

Drug Alias NameCDR-101

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Trispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionAnti-Programmed death-ligand 1Anti-BCMAAnti-CD3

TargetsProgrammed death-ligand 1T cell surface glycoprotein CD3B-cell maturation protein

Therapy Area/IndicationsMultiple Myeloma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesCDR-Life Inc

China Registration ClassN/A

Develop Information

Active CompaniesCDR-Life Inc

Inactive CompaniesN/A

Active IndicationsMultiple Myeloma

Inactive IndicationsN/A

Other Information

ATC CodeN/A